Salute e Benessere
Post-Traumatic Stress Disorder Market Set to Expand Significantly During the Study Period (2020-2034) with Pipeline Innovation and Unmet Needs | DelveInsight
Discover PTSD new treatment @
The post-traumatic stress disorder market dynamics are expected to change in the coming years. The , along with the modeled on the condition, such as prolonged duress stress disorder and post-traumatic grief disorder, has significantly expanded the patient pool, creating a ; coupled with the , this is poised to drive major positive growth in the global PTSD medications market and offer renewed hope to patients.
As potential therapies are being investigated for the treatment of post-traumatic stress disorder, it is safe to predict that the treatment space will significantly impact the post-traumatic stress disorder market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the post-traumatic stress disorder market in the 7MM.
However, several factors may impede the growth of the post-traumatic stress disorder market. Post-traumatic stress disorder is associated with , including alcohol and drug abuse, leading to . The considerable symptom overlap with other behavioral health conditions, partly due to the such as numbness and dysphoria, which are also common in major depressive disorder, makes accurate diagnosis challenging. Furthermore, of PTSD contribute to negative societal attitudes and discrimination toward affected individuals.
Moreover, post-traumatic stress disorder treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the post-traumatic stress disorder market growth may be offset by , , , and a . In addition, the about the disease may also impact the post-traumatic stress disorder market growth.
Managing PTSD in patients requires a comprehensive, multidimensional approach. Key treatment components include educating the patient, providing social support, and addressing anxiety through both psychotherapy and medication. Education and social support serve as crucial early steps to help patients engage with care and lessen the effects of trauma. Treatment typically combines .
Psychotherapy plays a central role in helping individuals with PTSD manage symptoms and build effective coping strategies. It also aims to educate both patients and their families about the condition and assist them in confronting trauma-related fears. Various therapeutic methods are used, including , among others.
are considered first-line medications due to their ability to boost serotonin levels, helping relieve anxiety and fear. , both approved by the FDA, are commonly used. Buspirone, a partial agonist at the serotonin 1A receptor, may help reduce anxiety, though its effects take time to manifest.
Despite their frequent use, benzodiazepines lack evidence for improving core PTSD symptoms. Other medications like target hyperarousal, while β-blockers such as propranolol have been studied for potential preventive effects when given soon after trauma. Anticonvulsants like show limited supporting data.
are considered second-line options due to adverse effects. Trials with and D-cycloserine have yielded minimal benefits. Additional adjunctive treatments, including for nightmares for emotional numbing like valproate and lamotrigine, have shown variable results.
To know more about FDA-approved drugs for PTSD, visit @
The PTSD pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. Expected launch of emerging therapies, such as (Otsuka Pharmaceutical), (Bionomics Limited), (Compass Pathways), and others shall further create a positive impact on the market.
The combination of is currently under investigation as a potential treatment for PTSD. Brexpiprazole is a novel serotonin-dopamine activity modulator (SDAM), acting as a partial agonist at dopamine D2 and serotonin 1A receptors, and as a potent antagonist at serotonin 2A, and noradrenergic alpha 1B and 2C receptors. Sertraline, marketed as ZOLOFT, is a selective serotonin reuptake inhibitor (SSRI) commonly used to manage depression, panic disorder, anxiety, and obsessive-compulsive symptoms by balancing brain chemicals involved in mood regulation.
In January 2025 , Otsuka Pharmaceutical announced that the FDA would convene a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to evaluate the Supplemental New Drug Application (sNDA) for the brexpiprazole-sertraline combination in the treatment of adult PTSD. This advisory meeting, anticipated in the first half of 2025, has postponed the initial Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025 .
Separately, is developing , a proprietary compound intended for the treatment of Social Anxiety Disorder (SAD), PTSD, and other anxiety-related conditions. BNC210 functions as a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR) and has demonstrated therapeutic potential in both preclinical and clinical settings due to its unique mechanism of action.
In December 2024 , Bionomics reported positive findings from its , which were published in NEJM Evidence and presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) during the inaugural 'Promising Targets' session.
The anticipated launch of these emerging therapies are poised to transform the post-traumatic stress disorder market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the post-traumatic stress disorder market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about post-traumatic stress disorder drugs in development @
Post-traumatic stress disorder is a psychiatric condition that can arise after exposure to traumatic events like natural disasters, severe accidents, war, rape, or threats of serious harm. Individuals with PTSD often suffer from recurring distressing thoughts, nightmares, or flashbacks of the event, accompanied by intense emotions such as fear, anger, or sadness. They may feel emotionally numb, avoid trauma-related triggers, and react strongly to seemingly normal stimuli. These symptoms can emerge shortly after the trauma or surface years later, affecting daily life, relationships, and overall functioning.
PTSD symptoms are categorized into intrusive memories, avoidance, negative changes in mood and cognition, and heightened arousal or reactivity. A diagnosis is made if these symptoms persist for more than a month and cause significant distress or impairment. While no specific lab tests exist for PTSD, healthcare providers typically begin with a medical history and physical exam to rule out other causes. If no physical issue is found, a referral to a mental health specialist is made for further evaluation through structured assessments and interviews.
The post-traumatic stress disorder epidemiology section provides insights into the historical and current post-traumatic stress disorder patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The post-traumatic stress disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand which factors are driving post-traumatic stress disorder market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PTSD companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted PTSD epidemiology in the 7MM, i.e., the United States , EU5 ( Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key LEMS companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key LEMS companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/post-traumatic-stress-disorder-market-set-to-expand-significantly-during-the-study-period-20202034-with-pipeline-innovation-and-unmet-needs--delveinsight-302492046.html